On June 28, 2022, our company's product levetiracetam concentrated solution for injection (5ml:500mg) was approved by the State Drug Administration for drug marketing. 
    Levetiracetam concentrated solution for injection (5ml:500mg) of our company was developed with Keppra® as the reference preparation according to the technical requirements of consistency evaluation of quality and efficacy.
    Levetiracetam, a derivative of pyrrolidone, can suppress epileptoid bursts in hippocampus without affecting normal neuronal excitability, and may selectively suppress the hypersynchronization of epileptoid bursts and the spread of seizures. This product is used for the treatment of partial seizures (with or without secondary seizures) in adults and children over 4 years of age with epilepsy, and can be used as an alternative to oral administration when the patient is temporarily unable to take oral preparations.